Product image of Myfenax (Mycophenolate Mofetil) supplied by GNH India

Myfenax

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Myfenax (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myfenax, is an antimetabolite presented as a tablet for oral use. It is employed to prevent rejection of transplanted organs in patients who have received kidney, liver, heart or other solid‑organ transplants.

GNH India supplies Myfenax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times, secure packaging and responsive technical support throughout the supply chain.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myfenax, containing mycophenolate mofetil, is used in the immunosuppressive management of solid‑organ transplantation, often as part of a combination regimen with calcineurin inhibitors and steroids.

  • Kidney transplantation: helps prevent acute and chronic graft rejection.
  • Liver transplantation: reduces the incidence of rejection episodes and supports graft survival.
  • Heart transplantation: provides maintenance immunosuppression to lower rejection risk.
  • Pancreas transplantation: contributes to rejection prophylaxis and improves graft function.
  • Lung transplantation: aids in preventing graft rejection and supports long‑term graft viability.

How It Works

  • Mycophenolate mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), a key catalyst in the de novo synthesis of guanine nucleotides. By depleting guanosine triphosphate pools, the drug impairs proliferation of activated T‑lymphocytes and B‑lymphocytes, which rely on this pathway for DNA synthesis, thereby attenuating the immune response that leads to graft rejection. The inhibition is reversible and preferentially affects lymphocytes because other cell types can utilize salvage pathways for purine synthesis.

Side Effects

Myfenax may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools.
  • Headache: transient cranial discomfort.
  • Tremor: mild shaking of hands or limbs.
  • Vomiting: occasional episodes of emesis.
  • Abdominal pain: cramp‑like discomfort.
  • Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

  • Infections: opportunistic or severe bacterial, viral or fungal infections.
  • Bone marrow suppression: leukopenia, anemia or thrombocytopenia.
  • Malignancy: increased risk of lymphoproliferative disorders and skin cancers.
  • Liver enzyme elevation: increased transaminases indicating hepatic stress.
  • Pregnancy loss: fetal malformations and embryotoxicity (category X).

Precautions & Warnings

When prescribing Myfenax, clinicians should observe several precautionary measures to minimize risk.

  • Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia.
  • Assess renal function: adjust dosing in patients with impaired kidney function.
  • Avoid pregnancy: discontinue before conception and use effective contraception.
  • Vaccination caution: avoid live vaccines during treatment.
  • Drug interactions: review concomitant medications that may increase mycophenolate exposure.
  • Store at room temperature: keep tablets below 25 °C in the original container, protected from moisture.

Avoid Interactions

Myfenax can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Live vaccines: may cause severe infection due to immunosuppression.
  • Azathioprine: additive bone marrow suppression increases risk of cytopenias.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may reduce mycophenolate absorption; separate dosing by at least 2 hours.
  • Cyclosporine or tacrolimus: may increase mycophenolate exposure; monitor drug levels and adjust dose.
  • Warfarin: may enhance anticoagulant effect; check INR more frequently.

Frequently Asked Questions

Myfenax contains mycophenolate mofetil and is indicated to prevent rejection of transplanted organs such as kidney, liver, heart and other solid‑organ grafts. It is administered as part of a multi‑drug immunosuppressive regimen in transplant recipients.

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase, blocking the de novo synthesis of guanine nucleotides. This limits the proliferation of activated T‑ and B‑lymphocytes, thereby reducing the immune response that can damage a transplanted organ.

The dosing regimen for Myfenax is individualized by the prescribing clinician. Factors such as the type of transplant, patient weight, renal function and concomitant immunosuppressants determine the appropriate dose and schedule.

Mycophenolate mofetil is classified as pregnancy category X because it can cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be stopped before conception. Breastfeeding is not recommended as the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative is azathioprine, another antimetabolite used in transplant immunosuppression. Mycophenolate mofetil generally offers more potent inhibition of lymphocyte proliferation and a different side‑effect profile, but both agents require careful monitoring of blood counts and renal function.

Myfenax tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Myfenax is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The tablets are swallowed whole and should not be split, crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include severe infections due to immunosuppression, bone‑marrow suppression leading to leukopenia or anemia, and an increased risk of certain malignancies such as lymphoproliferative disorders. Regular monitoring for infection signs, blood‑count changes and unexpected symptoms is essential.

Myfenax is contraindicated in patients who are pregnant, planning to become pregnant, or breastfeeding. It should also be avoided in individuals with known hypersensitivity to mycophenolate mofetil or any tablet excipients, and in those with uncontrolled infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT